IllustrativeDolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A clinical trial found that dolutegravir restores gut microbiota in late-stage hiv-1, differing from darunavir in this effect. The trial was open-label and randomized. The study's results suggest a distinction between the two treatments in terms of their impact on gut microbiota in late-stage hiv-1 patients.